For Q3 of the fiscal year ending December 2026, consolidated revenue was 3,063 million yen, up 3.3% year-over-year, and operating income improved substantially to 205 million yen. Reflecting the exclusion of physician-supervised product development and sales as discontinued operations, profit before tax was 201 million yen. Full-year forecast expects revenue of 3,950 million yen and operating income of 195 million yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"6034","jir_company_name":"MRT Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/6034-20261113-01.pdf","jir_short_summary":"For Q3 of the fiscal year ending December 2026, consolidated revenue was 3,063 million yen, up 3.3% year-over-year, and operating income improved substantially to 205 million yen. Reflecting the exclusion of physician-supervised product development and sales as discontinued operations, profit before tax was 201 million yen. Full-year forecast expects revenue of 3,950 million yen and operating income of 195 million yen.","jir_summary":"### Performance Overview\nFor Q3 of the fiscal year ending December 2026, consolidated revenue was 3,063 million yen, representing a 3.3% increase year-over-year. Contribution from physician value-creation activities continued, and the impact of excluding physician-supervised product development and sales as discontinued operations is reflected. Operating income increased significantly to 205 million yen, and profit before tax remained solid at 201 million yen.\n\n### Full-Year Outlook and Investment Plan\nFull-year revenue is forecast at 3,950 million yen and operating income at 195 million yen. The company will continue to invest proactively in building its membership base and in overseas operations, aiming for record revenue from permanent (career change) placement services. Since the outlook assumes exclusion of discontinued operations, attention should be paid to related caveats going forward.","jir_financial_highlights":"Revenue: 3,063 (Up 3.3% Year-over-Year)\nOperating Income: 205 (Up 85 Year-over-Year)\nProfit Before Tax: 201 (Up 77 Year-over-Year)\nNet Income Attributable to Owners of Parent: 114 (Up 38 Year-over-Year)","jir_category":"","jir_hashtags":"#MRTIncIR, #Earnings, #EarningsGuidance","jir_key_figures":"Revenue: 3,063 million yen\nOperating Income: 205 million yen\nNet Income Attributable to Owners of Parent: 114 million yen","jir_meta_title":"MRT Inc. Q3 FY2026 Supplementary Earnings Materials | Revenue 3,063 million yen, Operating Income 205 million yen","jir_meta_description":"Summary of MRT Inc.'s Q3 FY2026 earnings and outlook: revenue 3,063 million yen, operating income 205 million yen, profit before tax 201 million yen, and full-year forecast and investment strategy explained.","jir_og_title":"MRT Inc. Q3 FY2026 Supplementary Earnings Materials","jir_og_description":"MRT Inc.'s Q3 results: revenue 3,063 million yen and operating income 205 million yen. Full-year forecast: revenue 3,950 million yen and operating income 195 million yen; continued overseas investment and membership expansion.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60509,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-153117","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n